Old Web
English
Sign In
Acemap
>
authorDetail
>
Tiffany Lin
Tiffany Lin
Novartis
Ceritinib
Pharmacokinetics
Medicine
Anaplastic lymphoma kinase
Pharmacology
3
Papers
68
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (3)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Assessment of drug–drug interaction potential between ceritinib and proton pump inhibitors in healthy subjects and in patients with ALK-positive non-small cell lung cancer
2017
Cancer Chemotherapy and Pharmacology
Yvonne Y. Lau
Wen Gu
Tiffany Lin
Kalyanee Viraswami-Appanna
Can Cai
Jeffrey W. Scott
Michael Shi
Show All
Source
Cite
Save
Citations (12)
Effects of meal type on the oral bioavailability of the ALK inhibitor ceritinib in healthy adult subjects
2016
The Journal of Clinical Pharmacology
Yvonne Y. Lau
Wen Gu
Tiffany Lin
Dongweon Song
Richard Yu
Jeffrey W. Scott
Show All
Source
Cite
Save
Citations (32)
Phase I study of ceritinib in pediatric patients (Pts) with malignancies harboring a genetic alteration in ALK (ALK+): Safety, pharmacokinetic (PK), and efficacy results.
2015
Journal of Clinical Oncology
Birgit Geoerger
Johannes H. Schulte
Christian M. Zwaan
Michela Casanova
Matthias Fischer
Lucas Moreno
Toby Trahair
Irene Jiménez
Hyoung Jin Kang
Alberto S. Pappo
Eric Schafer
Brian Weiss
Mary Ellen Healy
Ke Li
Tiffany Lin
Anthony Boral
Andrew D.J. Pearson
Show All
Source
Cite
Save
Citations (24)
1